nasdaqahco
Mid-cap stocks are stocks that fall between large- and small-cap stocks. Though investors have lately dumped mid- and small-cap stocks due to macro uncertainty, analysts expect these two categories to see renewed interest from investors. Let’s take a look at the five worst and best performing mid-cap stocks in May 2022. Best Performing Mid-Cap Stocks In May 2022Q1 2022 hedge fund letters, conferences and more Founded in 1906 and headquartered in Sugar Land, Texas, this company is in the business of petroleum refining and marketing. CVR Energy, Inc. (NYSE:CVI) shares are up by over 130% year to...
ValueWalk
Jehoshaphat Research’s short report update on Adapthealth Corp (NASDAQ:AHCO). Q2 2021 hedge fund letters, conferences and more Executive Summary:We are short AHCO and believe that its downside is again around 50%, in large part due to its negative organic growth. However, we no longer have to argue our case with complex arithmetic and assumptions. There is now nothing more to debate – organic growth in both Q1 and Q2 2021 was indeed negative, more than 1,000 basis points below management’s claims. A new SEC filing disclosure confirms it. This disclosure is brand new, provided for the first tim...
ValueWalk
What’s New In ActivismBill Ackman was forced to rejig his deal to buy 10% of Vivendi’s Universal Music Group. The activist had struck a deal earlier in the year with Vivendi, worth $4 billion, that would have used up the majority of Ackman’s Pershing Square Tontine Holdings special purpose acquisition company (SPAC). Q2 2021 hedge fund letters, conferences and more Ackman’s investment in Universal Music will now go through his main hedge fund rather than the SPAC, after U.S. regulators questioned whether the deal with Vivendi adheres to New York Stock Exchange rules. In an open letter to share...
ValueWalk
Jehoshaphat Research is short Adapthealth Corp (NASDAQ:AHCO). Q2 2021 hedge fund letters, conferences and more We believe that AdaptHealth (NASDAQ:AHCO), a roll-up of roll-ups with excessive debt, is deceiving the investor community via its financial reporting practices. While management claims (and consensus estimates reflect) an organic growth trajectory of 8-10%, AHCO is in fact experiencing double-digit organic decline. It is also, in our opinion, taking steps to obscure that decline which are expressly forbidden by the SEC.i This may explain the recent departures of the CFO, CSO, CTO and ...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら